Fundraising FoxGeneLancet Biosciences
1 known investors
Find your way into GeneLancet Biosciences
Sign up to see every warm intro you have to GeneLancet Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GeneLancet Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GeneLancet develops proprietary LgRNA technology for precise gene editing, with applications in CRISPR polymerase-directed therapies targeting neurodegenerative diseases and cancers with unmet medical needs.
Founders & leadership
SL
Sheri LinSheri Lin is founder and CEO of GeneLancet Biosciences, which develops nucleoside and nucleotide chemistry for applications in gene editing, therapeutics, and genomics research.
Investors · 1
Related companies · 1
Companies working in the same space as GeneLancet Biosciences.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does GeneLancet Biosciences do?
- GeneLancet develops proprietary LgRNA technology for precise gene editing, with applications in CRISPR polymerase-directed therapies targeting neurodegenerative diseases and cancers with unmet medical needs.
- Who are GeneLancet Biosciences's investors?
- GeneLancet Biosciences's investors include The Innovation Space.